Tag: action

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace’s comprehensive suite of technologies for its growing customer base

Dhaka, Bangladesh, June 18, 2026 (GLOBE NEWSWIRE) -- BABU88, a leading online gaming and sports betting platform, has proudly announced its sponsorship of the Antwerp Anchors (ANA) for this season of EUT20 Belgium 2026. This strategic partnership highlights BABU88's commitment to sports development and solidifies its presence in the international cricket community.

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investors of the July 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.